Demographics and clinical characteristics of subjects with and without asthma
| Subjects with asthma | Subjects without asthma | |
|---|---|---|
| Frequency (%) (except*) | Frequency (%) (except*) | |
| Total no. included for analysis | 28 | 46 |
| Median age (range) | 29 (18–70)* | 22 (18–73)* |
| Sex: male | 11 (39) | 23 (50) |
| Ethnic group | ||
| Asian or Asian British | 1 (3.6) | 5 (10.9) |
| Black or Black British | 4 (14.3) | 0 (0) |
| Mixed ethnicity | 1 (3.6) | 0 (0) |
| White or White British | 22 (78.6) | 41 (89.1) |
| Smoking history | ||
| Current | 5 (17.9) | 5 (10.9) |
| Ex-smokers | 4 (14.3) | 9 (19.6) |
| Non-smokers | 19 (67.9) | 32 (69.6) |
| Positive family history of asthma | 13 (46.4) | 21 (45.7) |
| History/symptoms of GO reflux | 5 (17.9) | 9 (19.6) |
| History/symptoms of eczema | 4 (14.3) | 6 (13.0) |
| History/symptoms of rhinitis | 9 (32.1) | 8 (17.4) |
| History/symptoms of hay fever | 12 (42.9) | 20 (43.5) |
| History of NSAID allergy | 1 (3.6) | 1 (2.2) |
| Positive skin prick for ≥1 aeroallergen | 17 (60.7) | 26 (56.5) |
| Mean (SD) | Mean (SD) | |
| FEV1% predicted | 86.7 (14.0) | 96.9 (15.6) |
| FEV1:FVC ratio (%) | 76 (10) | 82.1 (8.4) |
| Reversibility (%) | 12.6 (11.7) | 3.6 (6.3) |
| Blood eosinophil count (×109/L)† | 0.35 (0.4) | 0.2 (0.1) |
| Baseline ACQ score | 1.96 (0.81) | 1.42 (0.82) |
| Baseline ACT score | 15.8 (4.4) | 17.2 (4.2) |
†Data presented are median and IQR as variable not normally distributed.
ACQ, asthma control questionnaire; ACT, asthma control test; GO, gastro-oesophageal; NSAID, non-steroidal anti-inflammatory drug.